Please see below information sent by NICE, which may be of interest to some BSODR members:

Dear­­ Technology Appraisal and Highly Specialised Technologies stakeholders

Consultation on changes to the Technology Appraisals and Highly Specialised Technologies programmes

Yesterday, NICE and NHS England launched a joint 12 week consultation on changes to the arrangements for evaluating and funding drugs and other health technologies appraised through NICE’s Technology Appraisal (TA) and Highly Specialised Technologies (HST) programmes.

As your organisation is a stakeholder in NICE’s TA and/or HST programme, I am writing to inform you of the details of this new consultation and to invite you to take part.

NICE and NHS England intend to work together more closely to better manage access to new drugs and medical technologies (devices and diagnostics) by simplifying and speeding up some appraisals, and by making the arrangements for funding others more clear. The proposed changes will benefit patients by providing access to the most effective and cost-effective new treatments more quickly and will help the life sciences industry by increasing the opportunities for companies to help manage the introduction of their new technologies into the NHS.

The NHS is committed to providing timely access to new treatments, but introducing new technologies in a way that is both good for UK business and, at the same time, optimises the financial sustainability of the NHS can be challenging. This consultation sets out a number of ways in which NICE and NHS England can provide an environment that encourages the life sciences industry and the NHS to work together in the best interests of patients. By facilitating collaboration and providing opportunities for early dialogue between innovators and the NHS, and by speeding up appraisal and adoption processes, NICE and NHS England can enable the development of arrangements that deliver the right outcomes for both patients and the life sciences industry.

Summary of proposals

·           Introduce a ‘fast track’ NICE technology appraisal process for the most promising new technologies, which fall below an incremental cost-effectiveness ratio of £10,000 per QALY (quality adjusted life year), to get these treatments to patients more quickly. 

·           Operate a ‘budget impact threshold’ of £20 million, set by NHS England, to signal the need for a dialogue with companies to agree special arrangements to better manage the introduction of new technologies recommended by NICE. This would apply to a small number of technologies that, once determined as cost effective by NICE, would have a significant impact on the NHS budget. 

·           Vary the timescale for the funding requirement when the budget impact threshold is reached or exceeded, and there is therefore a compelling case that the introduction of the new technology would risk disruption to the funding of other services. 

·           Automatically fund, from routine commissioning budgets, treatments for very rare conditions (highly specialised technologies) up to £100,000 per QALY (5 times greater than the lower end of NICE’s standard threshold range), and provide the opportunity for treatments above this range to be considered through NHS England’s process for prioritising other highly specialised technologies. 

The consultation is available via the NICE website: and will run from Thursday 13 October 2016 until Friday 13 January 2017.

We would like to receive comments on the proposals from anyone who has an interest in the TA and HST programmes. Comments can be made via the pro-forma that is available on the consultation webpage. 

We will also be providing stakeholders with the opportunity to discuss the proposals during the consultation period at the following events: 

·         1 – 2.30pm on 3 November 2016 (register for this webinar)
·         1 – 2.30pm on 17 November 2016 (register for this webinar)
·         1 – 2.30pm on 20 December 2016 (register for this webinar)
·         1 – 2.30pm on 12 January 2017 (register for this webinar)

Face-to-face events:
·         2 – 4.30pm on 29 November 2016 – central London TBC
·         2 – 4.30pm on 13 December 2016 – central Manchester TBC 

To register to attend the face-to-face events, please complete the nomination form and email to

17 October 2016